Pulmonary artery hypertension: New drug treatment in children

Archives of Disease in Childhood: Education and Practice Edition

Volumn 90, Issue 1, 2005, Pages

  Ford, Katrina ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARGININE; BERAPROST; BOSENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; ORPHAN DRUG; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNIPROST; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; WARFARIN;

ARTHRALGIA; CHILD; CHILD CARE; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG COST; DRUG DELIVERY SYSTEM; DYSPNEA; EVIDENCE BASED MEDICINE; FLUSHING; HUMAN; JAW; LIVER DYSFUNCTION; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SINUSITIS; SYNCOPE; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION;

EID: 20144384361     PISSN: 17430585     EISSN: None     Source Type: Journal    
DOI: 10.1136/adc.2004.059113     Document Type: Review

References (51)

1. D'Alonso GE, Barst RJ, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1991;115:434-49.
2. Gaine SP, Rubin U. Primary pulmonary hypertension. Lancet 1998;352:719-25.
3. Galie N, Rubin LJ. Introduction: new insights into a challenging disease. A review of the Third World Symposium on Pulmonary Artery Hypertension. J Am Coll Cardiol 2004;43(12 suppl):1S.
4. Rubin LJ. Introduction: diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:7S-10S.
5. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary artery hypertension. N Engl J Med 2004;351:1425-36.
6. Rosenzweig EB, Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Pediarr Pulmonol 2004;38:2-22.
7. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999;99:1197-208.
8. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
9. Badesh DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
10. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 2000;102:2781-91.
11. Yung D, Widlitz AC, Rosenzweig EG, et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004;110:660-5.
12. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984;70:580-7.
13. Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J 2003;21:155-70.
14. Badesh DB, McLaughlin VV, Delcroix M. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56S-61S.
15. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993;70:366-70.
16. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996;34:296-302.
17. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
18. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
19. McLaughlin W, Shillington A, Rich S. Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation 2002;106:1477-82.
20. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary hypertension. Chest 2003;124:1612-1615.
21. Schering Health Care Limited. Summary of product characteristics: iloprost (Ventavis®). http://emc.medicines.org.uk/(accessed 19 April 2004).
22. Goldsmith DR, Wagstaff AJ. Inhaled iloprost: in primary pulmonary hypertension. Drugs 2004;64:763-73.
23. Olschewski H, Simonneau G. Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
24. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;105:800-4.
25. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502.
26. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25.
27. Kim NHS, Rubin LJR. Endothelin in health and disease: Endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Therapeut 2002;7:9-19.
28. Dupois J. Endothelin-receptor antagonists in pulmonary hypertension. Lancet 2001;356:1113-4.
29. Rich S, McLaughlin W. Endothelin receptor blockers in cardiovascular disease Circulation 2003;108:2184-90.
30. Actelion Pharmaceuticals UK. Summary of product characteristics: bosentan (Tracleer®). http://emc.medicines.org.uk/(accessed 19 April 2004).
31. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
32. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54.
33. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
34. McLaughlin V, Sitbon O, Rubin U, et al. The effect of first line bosentan on survival of patients with primary pulmonary hypertension. American Thoracic Society, 99th International Conference, Seattle, 10-21 May, 2003.
35. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Therapeutics 2003;73:372-82.
36. Vogel M, Maiya S, Haworth SG. Current experience with bosentan (Tracleer) in the treatment of pediatric patients with pulmonary arterial hypertension. Association of European Paediatric Cardiology, 38th Annual Meeting, Amsterdam, 28-31 May 2003 Abstract 195.
37. Penny DJ, Rose M, Wilson S, et al. Preliminary experience with bosentan in children with primary pulmonary hypertension [abstract]. J Am Coll Cardiol 2003;41(suppl A).
38. Cooke JP. A novel mechanism for pulmonary arterial hypertension. Circulation 2003;108:1420-21.
39. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal Anesthesiology 1999;91:307-10.
40. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000;84:E4.
41. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343:1342.
42. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9.
43. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 2003;108:239-44.
44. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-9.
45. Humbert M, Barst RJ, Robbins IM, et al. Safety and efficacy of bosentan combined with epoprostenol in patients with severe pulmonary artery hypertension. Am J Respir Crit Care Med 2003;167:A441.
46. Rayburn BK, Benza RL, Tallaj JA, et al. The use of bosentan and a prostacyclin analogue in the treatment of primary pulmonary hypertension. J Heart Lung Transplant 2003;22(1S):abstract 241.
47. Bhatia S, Frantz RP, Severson CJ, et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003;78:1207-13.
48. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-64.
49. Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123:1293-5.
50. Langleben D, Christman BW, Barst RJ, et al. Effects of thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002;143:E4.
51. Barst RJ, Langleben D, Frost A, et al. Sitaxentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.